Ricky Quoc Ngo

Array ( [id] => 19186350 [patent_doc_number] => 20240165263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => TARGETING MULTIPLE T CELL TYPES USING SPHERICAL NUCLEIC ACID VACCINE ARCHITECTURE [patent_app_type] => utility [patent_app_number] => 18/283699 [patent_app_country] => US [patent_app_date] => 2022-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -92 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19188128 [patent_doc_number] => 20240167041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => LOSS OF LIPID KINASE PI5P4K GAMMA RESTRICTS TUMOR GROWTH [patent_app_type] => utility [patent_app_number] => 18/281526 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18281526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805798 [patent_doc_number] => 20220257633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION [patent_app_type] => utility [patent_app_number] => 17/671688 [patent_app_country] => US [patent_app_date] => 2022-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17671688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792465 [patent_doc_number] => 20220251556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/590754 [patent_app_country] => US [patent_app_date] => 2022-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760102 [patent_doc_number] => 20220233714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => NANOGOLD-DNA BIOCONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/586560 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003894 [patent_doc_number] => 20240067965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 [patent_app_type] => utility [patent_app_number] => 18/256632 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -115 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916352 [patent_doc_number] => 12291708 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Oral delivery of antisense conjugates targeting PCSK9 [patent_app_type] => utility [patent_app_number] => 17/547879 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 50797 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655347 [patent_doc_number] => 20220175812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => POLYMER NANOPARTICLE AND DNA NANOSTRUCTURE COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY [patent_app_type] => utility [patent_app_number] => 17/542055 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17673056 [patent_doc_number] => 20220186223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => T-LYMPHOCYTE BINDING APTAMERS [patent_app_type] => utility [patent_app_number] => 17/542046 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657418 [patent_doc_number] => 20220177883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => Antisense Oligonucleotides Targeting ATXN3 [patent_app_type] => utility [patent_app_number] => 17/540569 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17540569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208462 [patent_doc_number] => 20230054720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => Antisense Oligonucleotides Targeting ATXN3 [patent_app_type] => utility [patent_app_number] => 17/540495 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17540495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625735 [patent_doc_number] => 20220160750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => SINGLE-NUCLEI CHARACTERIZATION OF AMYOTROPHIC LATERAL SCLEROSIS FRONTAL CORTEX [patent_app_type] => utility [patent_app_number] => 17/535070 [patent_app_country] => US [patent_app_date] => 2021-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17535070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505513 [patent_doc_number] => 20220098615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => DUAL FUNCTIONAL EXPRESSION VECTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/456239 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17456239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749936 [patent_doc_number] => 20220228141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => OLIGONUCLEOTIDES FOR DGAT2 MODULATION [patent_app_type] => utility [patent_app_number] => 17/532636 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625733 [patent_doc_number] => 20220160748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING [patent_app_type] => utility [patent_app_number] => 17/455528 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17455528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792510 [patent_doc_number] => 20220251601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => mRNA NANOCAPSULE AND USE IN PREPARATION OF ANTIVIRAL DRUGS [patent_app_type] => utility [patent_app_number] => 17/528851 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860277 [patent_doc_number] => 20230414711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING [patent_app_type] => utility [patent_app_number] => 18/036704 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18862303 [patent_doc_number] => 20230416739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => B-SPECTRIN (SPTBN1) DEFICIENCY PROTECTS MICE FROM HIGH-FAT DIET-INDUCED LIVER DISEASE AND CANCER DEVELOPMENT [patent_app_type] => utility [patent_app_number] => 18/252771 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627595 [patent_doc_number] => 20220162610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => NOVEL RNA TRANSCRIPT [patent_app_type] => utility [patent_app_number] => 17/524586 [patent_app_country] => US [patent_app_date] => 2021-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17524586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670945 [patent_doc_number] => 20220184112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/522418 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522418 [rel_patent_id] =>[rel_patent_doc_number] =>)